Hypoxia‐inducible factor‐2α (HIF‐2α), but not HIF‐1α, is essential for hypoxic induction of class III β‐tubulin expression in human glioblastoma cells
Glioblastoma multiforme (GBM) is the deadliest form of primary brain cancer. Several reports have indicated aberrant levels of βIII‐tubulin (βIII‐t) in human GBM. βIII‐t overexpression was linked to increasing malignancy in glial tumors and described to determine the onset of resistance to chemother...
Saved in:
Published in | The FEBS journal Vol. 281; no. 23; pp. 5220 - 5236 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
Published by Blackwell Pub. on behalf of the Federation of European Biochemical Societies
01.12.2014
Wiley |
Subjects | |
Online Access | Get full text |
ISSN | 1742-464X 1742-4658 1742-4658 |
DOI | 10.1111/febs.13062 |
Cover
Abstract | Glioblastoma multiforme (GBM) is the deadliest form of primary brain cancer. Several reports have indicated aberrant levels of βIII‐tubulin (βIII‐t) in human GBM. βIII‐t overexpression was linked to increasing malignancy in glial tumors and described to determine the onset of resistance to chemotherapy. Furthermore, a linkage was suggested between the induction of βIII‐t expression and hypoxia, a hallmark of GBM. We investigated the role of hypoxia‐inducible factor (HIF)‐1α and HIF‐2α in the regulation of the βIII‐t gene (TUBB3) in GBM cells cultured in either normoxia or hypoxia. We report for the first time that HIF‐2α, but not HIF‐1α, is involved in hypoxia‐induced βIII‐t expression in GBM cells. By gene‐reporter experiments and site‐directed mutagenesis, we found that two overlapping hypoxia response elements located in the 3′ UTR of the gene were involved in the activation of TUBB3. This occurred through an enhanced binding of HIF‐2α to the 3′ region, as revealed by an electrophoretic mobility shift assay. Conversely, the promoter of TUBB3 was shown to be inactive. In addition, we observed that HIF‐1α exhibits a repressive effect on βIII‐t expression in cells cultured in normoxia. These results show that both HIF‐α isoforms have opposing effects on βIII‐t expression in GBM cells. Finally, we observed that hypoxia‐induced βIII‐t expression is well correlated with the kinetics of HIF‐2α protein stabilization. The evidence for a direct linkage between HIF‐2α and increased expression of βIII‐t by hypoxia suggests that an anti‐HIF‐2α strategy (i.e. by downregulating βIII‐t) could be of potential interest for improving the treatment of GBM. |
---|---|
AbstractList | Glioblastoma multiforme (GBM) is the deadliest form of primary brain cancer. Several reports have indicated aberrant levels of βIII‐tubulin (βIII‐t) in human GBM. βIII‐t overexpression was linked to increasing malignancy in glial tumors and described to determine the onset of resistance to chemotherapy. Furthermore, a linkage was suggested between the induction of βIII‐t expression and hypoxia, a hallmark of GBM. We investigated the role of hypoxia‐inducible factor (HIF)‐1α and HIF‐2α in the regulation of the βIII‐t gene (TUBB3) in GBM cells cultured in either normoxia or hypoxia. We report for the first time that HIF‐2α, but not HIF‐1α, is involved in hypoxia‐induced βIII‐t expression in GBM cells. By gene‐reporter experiments and site‐directed mutagenesis, we found that two overlapping hypoxia response elements located in the 3′ UTR of the gene were involved in the activation of TUBB3. This occurred through an enhanced binding of HIF‐2α to the 3′ region, as revealed by an electrophoretic mobility shift assay. Conversely, the promoter of TUBB3 was shown to be inactive. In addition, we observed that HIF‐1α exhibits a repressive effect on βIII‐t expression in cells cultured in normoxia. These results show that both HIF‐α isoforms have opposing effects on βIII‐t expression in GBM cells. Finally, we observed that hypoxia‐induced βIII‐t expression is well correlated with the kinetics of HIF‐2α protein stabilization. The evidence for a direct linkage between HIF‐2α and increased expression of βIII‐t by hypoxia suggests that an anti‐HIF‐2α strategy (i.e. by downregulating βIII‐t) could be of potential interest for improving the treatment of GBM. Glioblastoma multiforme (GBM) is the deadliest form of primary brain cancer. Several reports have indicated aberrant levels of βIII-tubulin (βIII-t) in human GBM. βIII-t overexpression was linked to increasing malignancy in glial tumors and described to determine the onset of resistance to chemotherapy. Furthermore, a linkage was suggested between the induction of βIII-t expression and hypoxia, a hallmark of GBM. We investigated the role of hypoxia-inducible factor (HIF)-1α and HIF-2α in the regulation of the βIII-t gene (TUBB3) in GBM cells cultured in either normoxia or hypoxia. We report for the first time that HIF-2α, but not HIF-1α, is involved in hypoxia-induced βIII-t expression in GBM cells. By gene-reporter experiments and site-directed mutagenesis, we found that two overlapping hypoxia response elements located in the 3' UTR of the gene were involved in the activation of TUBB3. This occurred through an enhanced binding of HIF-2α to the 3' region, as revealed by an electrophoretic mobility shift assay. Conversely, the promoter of TUBB3 was shown to be inactive. In addition, we observed that HIF-1α exhibits a repressive effect on βIII-t expression in cells cultured in normoxia. These results show that both HIF-α isoforms have opposing effects on βIII-t expression in GBM cells. Finally, we observed that hypoxia-induced βIII-t expression is well correlated with the kinetics of HIF-2α protein stabilization. The evidence for a direct linkage between HIF-2α and increased expression of βIII-t by hypoxia suggests that an anti-HIF-2α strategy (i.e. by downregulating βIII-t) could be of potential interest for improving the treatment of GBM.Glioblastoma multiforme (GBM) is the deadliest form of primary brain cancer. Several reports have indicated aberrant levels of βIII-tubulin (βIII-t) in human GBM. βIII-t overexpression was linked to increasing malignancy in glial tumors and described to determine the onset of resistance to chemotherapy. Furthermore, a linkage was suggested between the induction of βIII-t expression and hypoxia, a hallmark of GBM. We investigated the role of hypoxia-inducible factor (HIF)-1α and HIF-2α in the regulation of the βIII-t gene (TUBB3) in GBM cells cultured in either normoxia or hypoxia. We report for the first time that HIF-2α, but not HIF-1α, is involved in hypoxia-induced βIII-t expression in GBM cells. By gene-reporter experiments and site-directed mutagenesis, we found that two overlapping hypoxia response elements located in the 3' UTR of the gene were involved in the activation of TUBB3. This occurred through an enhanced binding of HIF-2α to the 3' region, as revealed by an electrophoretic mobility shift assay. Conversely, the promoter of TUBB3 was shown to be inactive. In addition, we observed that HIF-1α exhibits a repressive effect on βIII-t expression in cells cultured in normoxia. These results show that both HIF-α isoforms have opposing effects on βIII-t expression in GBM cells. Finally, we observed that hypoxia-induced βIII-t expression is well correlated with the kinetics of HIF-2α protein stabilization. The evidence for a direct linkage between HIF-2α and increased expression of βIII-t by hypoxia suggests that an anti-HIF-2α strategy (i.e. by downregulating βIII-t) could be of potential interest for improving the treatment of GBM. Glioblastoma multiforme (GBM) is the deadliest form of primary brain cancer. Several reports have indicated aberrant levels of βIII‐tubulin (βIII‐t) in human GBM. βIII‐t overexpression was linked to increasing malignancy in glial tumors and described to determine the onset of resistance to chemotherapy. Furthermore, a linkage was suggested between the induction of βIII‐t expression and hypoxia, a hallmark of GBM. We investigated the role of hypoxia‐inducible factor (HIF)‐1α and HIF‐2α in the regulation of the βIII‐t gene ( TUBB3 ) in GBM cells cultured in either normoxia or hypoxia. We report for the first time that HIF‐2α, but not HIF‐1α, is involved in hypoxia‐induced βIII‐t expression in GBM cells. By gene‐reporter experiments and site‐directed mutagenesis, we found that two overlapping hypoxia response elements located in the 3′ UTR of the gene were involved in the activation of TUBB3 . This occurred through an enhanced binding of HIF‐2α to the 3′ region, as revealed by an electrophoretic mobility shift assay. Conversely, the promoter of TUBB3 was shown to be inactive. In addition, we observed that HIF‐1α exhibits a repressive effect on βIII‐t expression in cells cultured in normoxia. These results show that both HIF‐α isoforms have opposing effects on βIII‐t expression in GBM cells. Finally, we observed that hypoxia‐induced βIII‐t expression is well correlated with the kinetics of HIF‐2α protein stabilization. The evidence for a direct linkage between HIF‐2α and increased expression of βIII‐t by hypoxia suggests that an anti‐HIF‐2α strategy (i.e. by downregulating βIII‐t) could be of potential interest for improving the treatment of GBM. Glioblastoma multiforme (GBM) is the deadliest form of primary brain cancer. Several reports have indicated aberrant levels of beta III-tubulin ( beta III-t) in human GBM. beta III-t overexpression was linked to increasing malignancy in glial tumors and described to determine the onset of resistance to chemotherapy. Furthermore, a linkage was suggested between the induction of beta III-t expression and hypoxia, a hallmark of GBM. We investigated the role of hypoxia-inducible factor (HIF)-1 alpha and HIF-2 alpha in the regulation of the beta III-t gene (TUBB3) in GBM cells cultured in either normoxia or hypoxia. We report for the first time that HIF-2 alpha , but not HIF-1 alpha , is involved in hypoxia-induced beta III-t expression in GBM cells. By gene-reporter experiments and site-directed mutagenesis, we found that two overlapping hypoxia response elements located in the 3' UTR of the gene were involved in the activation of TUBB3. This occurred through an enhanced binding of HIF-2 alpha to the 3' region, as revealed by an electrophoretic mobility shift assay. Conversely, the promoter of TUBB3 was shown to be inactive. In addition, we observed that HIF-1 alpha exhibits a repressive effect on beta III-t expression in cells cultured in normoxia. These results show that both HIF- alpha isoforms have opposing effects on beta III-t expression in GBM cells. Finally, we observed that hypoxia-induced beta III-t expression is well correlated with the kinetics of HIF-2 alpha protein stabilization. The evidence for a direct linkage between HIF-2 alpha and increased expression of beta III-t by hypoxia suggests that an anti-HIF-2 alpha strategy (i.e. by downregulating beta III-t) could be of potential interest for improving the treatment of GBM. beta III-tubulin ( beta III-t) overexpression is linked to increasing malignancy and chemoresistance in glioblastoma (GBM). We report that HIF-2 alpha is involved in hypoxia-induced beta III-t expression in GBM cells through the binding on hypoxia response elements located in the 3'UTR. HIF-1 alpha exhibits a repressive effect on beta III-t expression. An anti-HIF-2 alpha strategy could be of potential interest to improve the treatment of GBM. Glioblastoma multiforme (GBM) is the deadliest form of primary brain cancer. Several reports have indicated aberrant levels of βIII‐tubulin (βIII‐t) in human GBM. βIII‐t overexpression was linked to increasing malignancy in glial tumors and described to determine the onset of resistance to chemotherapy. Furthermore, a linkage was suggested between the induction of βIII‐t expression and hypoxia, a hallmark of GBM. We investigated the role of hypoxia‐inducible factor (HIF)‐1α and HIF‐2α in the regulation of the βIII‐t gene (TUBB3) in GBM cells cultured in either normoxia or hypoxia. We report for the first time that HIF‐2α, but not HIF‐1α, is involved in hypoxia‐induced βIII‐t expression in GBM cells. By gene‐reporter experiments and site‐directed mutagenesis, we found that two overlapping hypoxia response elements located in the 3′ UTR of the gene were involved in the activation of TUBB3. This occurred through an enhanced binding of HIF‐2α to the 3′ region, as revealed by an electrophoretic mobility shift assay. Conversely, the promoter of TUBB3 was shown to be inactive. In addition, we observed that HIF‐1α exhibits a repressive effect on βIII‐t expression in cells cultured in normoxia. These results show that both HIF‐α isoforms have opposing effects on βIII‐t expression in GBM cells. Finally, we observed that hypoxia‐induced βIII‐t expression is well correlated with the kinetics of HIF‐2α protein stabilization. The evidence for a direct linkage between HIF‐2α and increased expression of βIII‐t by hypoxia suggests that an anti‐HIF‐2α strategy (i.e. by downregulating βIII‐t) could be of potential interest for improving the treatment of GBM. βIII‐tubulin (βIII‐t) overexpression is linked to increasing malignancy and chemoresistance in glioblastoma (GBM). We report that HIF‐2α is involved in hypoxia‐induced βIII‐t expression in GBM cells through the binding on hypoxia response elements located in the 3′UTR. HIF‐1α exhibits a repressive effect on βIII‐t expression. An anti‐HIF‐2α strategy could be of potential interest to improve the treatment of GBM. |
Author | Cuhna‐Alves, Leilane Bernaudin, Myriam Lechapt‐Zalcman, Emmanuèle Grandval, Alexandra Bordji, Karim |
Author_xml | – sequence: 1 fullname: Bordji, Karim – sequence: 2 fullname: Grandval, Alexandra – sequence: 3 fullname: Cuhna‐Alves, Leilane – sequence: 4 fullname: Lechapt‐Zalcman, Emmanuèle – sequence: 5 fullname: Bernaudin, Myriam |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25244496$$D View this record in MEDLINE/PubMed https://hal.science/hal-01626225$$DView record in HAL |
BookMark | eNqNkktuFDEQhlsoiDxgwwHAywRlgl_dYy9DlGFaGolFiMTOcrvtjJG7PdjdkNlxBA7BBcJB5hCcBPd0JguEgNq4XPr-X6WqOsz2Wt_qLHuO4BlK8droKp4hAgv8KDtAU4ontMjZ3kNOP-xnhzF-hJDklPMn2T7OMaWUFwfZ9_l65W-t_Pn1m23rXtnKaWCk6nxIJby5A8fzcjamJ6eg6jvQ-g6MNbS5OwU2Ah2jbjsrHTA-gOXWUYGtX2d9C7wByskYQVmWYPMjKbu-6p1tgb5dhaQeoPRb9o1swY2zvkp45xsJlHYuPs0eG-mifnb_HmXXs8v3F_PJ4t3b8uJ8MVGUcTxBEkKdV4yQSnNW12SqlCIM1kzVEhqU5wQXtclVgWpmUplJQyWqOB1APCVH2cnou5ROrIJtZFgLL62Yny_EUIOowAXG-WeU2OORXQX_qdexE42NQ7ey1b6PAsMUiGBE_omiglM-ZYTT_0Axw4QVPE_oi3u0rxpdP_S7220C4Aio4GMM2ghlOzkspAvSOoGgGM5HDOcjtueTJK9-k-xc_wijEf5inV7_hRSzyzdXO83LUWOkF_Im2Ciur3Aa6zCtnLMp-QXmjuVT |
CitedBy_id | crossref_primary_10_1186_s13550_023_01052_8 crossref_primary_10_1016_j_bbcan_2021_188607 crossref_primary_10_1016_j_jvssci_2020_09_003 crossref_primary_10_1038_s41416_022_01717_6 crossref_primary_10_3389_fcell_2021_607142 crossref_primary_10_1007_s13361_015_1270_3 crossref_primary_10_1016_j_spen_2015_03_009 crossref_primary_10_3892_or_2016_5309 crossref_primary_10_3390_ijms18071434 crossref_primary_10_3389_fcell_2022_851542 crossref_primary_10_1126_scitranslmed_aax2879 crossref_primary_10_1007_s12015_019_09942_y crossref_primary_10_4155_fmc_2018_0163 crossref_primary_10_3390_biomedicines10050986 crossref_primary_10_1186_s13287_015_0101_6 crossref_primary_10_3892_or_2015_4404 crossref_primary_10_1016_j_drudis_2018_05_003 crossref_primary_10_3390_ijms23115991 crossref_primary_10_3390_ijms23179563 crossref_primary_10_1021_acsmedchemlett_8b00060 crossref_primary_10_1158_1535_7163_MCT_22_0066 crossref_primary_10_3390_ph18030389 crossref_primary_10_3390_cancers16112089 crossref_primary_10_1007_s00018_021_04101_4 crossref_primary_10_1016_j_niox_2019_08_008 crossref_primary_10_1517_14712598_2015_1084281 crossref_primary_10_3390_cancers11091308 crossref_primary_10_17816_MAJ83594 |
Cites_doi | 10.1038/nrc2803 10.1158/0008-5472.CAN-07-0509 10.1093/emboj/17.11.3005 10.1215/15228517-2007-024 10.1007/s10555-007-9055-1 10.1016/j.tips.2005.11.009 10.1158/0008-5472.CAN-08-1135 10.1158/0008-5472.CAN-10-4142 10.1056/NEJMoa043330 10.1002/jcp.22813 10.1371/journal.pone.0021717 10.2174/187152011797378760 10.1158/1535-7163.MCT-07-2370 10.1182/blood-2010-10-314427 10.1016/j.freeradbiomed.2011.08.023 10.1016/j.cellsig.2009.10.004 10.1097/00005072-199311000-00013 10.1158/1078-0432.CCR-05-2715 10.1159/000339152 10.1158/0008-5472.CAN-04-3246 10.1158/0008-5472.CAN-12-1345 10.1215/15228517-2008-072 10.1038/sj.bjc.6603675 10.4161/cbt.3.11.1216 10.1128/MCB.23.24.9361-9374.2003 10.1128/MCB.25.13.5675-5686.2005 10.1002/jcp.22798 10.1038/nrc3183 10.1172/JCI0215451 10.1016/S0305-7372(03)00003-3 10.1002/hep.23597 10.1101/gad.12.2.149 10.1158/0008-5472.CAN-05-3345 10.1038/cdd.2008.21 10.1515/hsz-2012-0318 10.1371/journal.pone.0072358 10.1016/j.ccr.2006.08.026 10.1016/j.gde.2008.12.001 10.2174/138161212800626238 10.1073/pnas.0906432106 10.5858/2001-125-0613-ALOTNC 10.1038/bjc.2012.553 10.2174/138161212800626193 10.1093/annonc/mdi902 10.1002/jcp.21870 10.1158/1535-7163.MCT-05-0244 10.1016/j.ccr.2009.03.018 10.1016/j.gene.2014.03.037 10.1016/j.gene.2007.11.015 10.1096/fj.01-0125com 10.1007/BF00318141 10.1038/nrd3253 10.1016/j.tibs.2012.06.004 10.1242/jcs.035022 10.1074/jbc.M901790200 10.1158/0008-5472.CAN-09-4487 10.1091/mbc.e06-05-0419 10.1113/expphysiol.2005.030924 10.1038/nrn1408 |
ContentType | Journal Article |
Copyright | 2014 FEBS 2014 FEBS. Distributed under a Creative Commons Attribution 4.0 International License |
Copyright_xml | – notice: 2014 FEBS – notice: 2014 FEBS. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
DBID | FBQ AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7TK 7S9 L.6 1XC |
DOI | 10.1111/febs.13062 |
DatabaseName | AGRIS CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Neurosciences Abstracts AGRICOLA AGRICOLA - Academic Hyper Article en Ligne (HAL) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Neurosciences Abstracts AGRICOLA AGRICOLA - Academic |
DatabaseTitleList | AGRICOLA MEDLINE - Academic MEDLINE CrossRef Neurosciences Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Chemistry |
EISSN | 1742-4658 |
EndPage | 5236 |
ExternalDocumentID | oai_HAL_hal_01626225v1 25244496 10_1111_febs_13062 FEBS13062 US201600005987 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Centre National de la Recherche Scientifique (CNRS) – fundername: University of Caen‐Basse Normandie (UCBN) – fundername: French Ministère de l'Enseignement Supérieur et de la Recherche (MESR) |
GroupedDBID | --- -DZ -~X .3N .55 .GA .Y3 05W 0R~ 10A 1OC 29H 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 A8Z AAESR AAEVG AAHBH AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEFU ABEML ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFS ACGOF ACIWK ACMXC ACNCT ACPOU ACPRK ACSCC ACUHS ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUYR AFBPY AFEBI AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AHBTC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C1A C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM E3Z EAD EAP EAS EAU EBB EBC EBD EBS EBX EJD EMB EMK EMOBN EST ESX EX3 F00 F01 F04 F5P FBQ FIJ FUBAC G-S G.N GODZA GX1 H.X HF~ HGLYW HH5 HZI HZ~ IHE IX1 J0M KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MVM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OBS OIG OVD P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K RNS ROL RX1 SUPJJ SV3 TEORI TR2 TUS UB1 V8K W8V W99 WBFHL WBKPD WIH WIJ WIK WIN WOHZO WOQ WOW WQJ WXI WXSBR WYISQ X7M XG1 Y6R ~IA ~KM ~WT 24P AEUQT AFPWT OK1 WRC AAYXX AEYWJ AGYGG CITATION CGR CUY CVF ECM EIF NPM 7X8 AAMMB AEFGJ AGXDD AIDQK AIDYY ESTFP 7TK 7S9 L.6 1XC |
ID | FETCH-LOGICAL-c4892-1a00e5b833be98dd37ccc380d8cda0f155326df5c61d8f0d88af4a1b947ccc273 |
IEDL.DBID | DR2 |
ISSN | 1742-464X 1742-4658 |
IngestDate | Fri May 09 12:13:20 EDT 2025 Fri Sep 05 17:17:09 EDT 2025 Thu Jul 10 18:19:12 EDT 2025 Mon Sep 08 10:19:12 EDT 2025 Thu Apr 03 07:03:29 EDT 2025 Tue Jul 01 03:06:42 EDT 2025 Thu Apr 24 22:57:22 EDT 2025 Wed Jan 22 16:33:39 EST 2025 Thu Apr 03 09:42:13 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 23 |
Keywords | hypoxia HIF-1α βIII-tubulin HIF-2α glioblastoma cells |
Language | English |
License | 2014 FEBS. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4892-1a00e5b833be98dd37ccc380d8cda0f155326df5c61d8f0d88af4a1b947ccc273 |
Notes | http://dx.doi.org/10.1111/febs.13062 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-0778-3397 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/febs.13062 |
PMID | 25244496 |
PQID | 1628238695 |
PQPubID | 23479 |
PageCount | 17 |
ParticipantIDs | hal_primary_oai_HAL_hal_01626225v1 proquest_miscellaneous_2000013213 proquest_miscellaneous_1694978394 proquest_miscellaneous_1628238695 pubmed_primary_25244496 crossref_citationtrail_10_1111_febs_13062 crossref_primary_10_1111_febs_13062 wiley_primary_10_1111_febs_13062_FEBS13062 fao_agris_US201600005987 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | December 2014 |
PublicationDateYYYYMMDD | 2014-12-01 |
PublicationDate_xml | – month: 12 year: 2014 text: December 2014 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | The FEBS journal |
PublicationTitleAlternate | FEBS J |
PublicationYear | 2014 |
Publisher | Published by Blackwell Pub. on behalf of the Federation of European Biochemical Societies Wiley |
Publisher_xml | – name: Published by Blackwell Pub. on behalf of the Federation of European Biochemical Societies – name: Wiley |
References | 2010; 10 2011; 117 2002; 110 2004; 3 2008; 7 2011; 11 2004; 5 2005; 65 2012; 18 2008; 32 2013; 8 2012; 12 2005; 25 2009; 11 2010; 22 1998; 17 2006; 20 1991; 265 2006; 66 2006; 27 2011; 71 2009; 122 2007; 9 2008; 68 2013; 394 2001; 15 2009; 284 2010; 70 2009; 19 2007; 67 1998; 12 2009; 15 2010; 9 2007; 26 2012; 83 2007; 18 2005; 352 2006; 12 2013; 108 2006; 10 2005; 90 2008; 409 2008; 15 2012; 37 2007; 96 2011; 6 2012; 227 2001; 125 1999; 9 2013; 73 2011; 51 1993; 52 2009; 221 2005; 4 2003; 29 2013 2005; 16 2010; 51 2003; 23 2014; 542 2009; 106 e_1_2_8_28_1 e_1_2_8_24_1 e_1_2_8_47_1 e_1_2_8_26_1 e_1_2_8_49_1 e_1_2_8_5_1 e_1_2_8_7_1 e_1_2_8_9_1 e_1_2_8_20_1 e_1_2_8_22_1 e_1_2_8_45_1 e_1_2_8_64_1 e_1_2_8_62_1 e_1_2_8_41_1 e_1_2_8_60_1 e_1_2_8_17_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_59_1 e_1_2_8_15_1 e_1_2_8_57_1 Scigliano S (e_1_2_8_38_1) 2008; 32 Glantz MJ (e_1_2_8_16_1) 1999; 9 Mitic G (e_1_2_8_43_1) 2013 e_1_2_8_32_1 e_1_2_8_55_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_53_1 e_1_2_8_51_1 e_1_2_8_30_1 e_1_2_8_29_1 e_1_2_8_25_1 e_1_2_8_46_1 e_1_2_8_27_1 e_1_2_8_48_1 e_1_2_8_2_1 e_1_2_8_4_1 e_1_2_8_6_1 Chang SM (e_1_2_8_3_1) 2006; 20 e_1_2_8_8_1 e_1_2_8_21_1 e_1_2_8_42_1 e_1_2_8_23_1 e_1_2_8_44_1 e_1_2_8_63_1 e_1_2_8_40_1 e_1_2_8_61_1 e_1_2_8_18_1 e_1_2_8_39_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_37_1 e_1_2_8_58_1 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_56_1 e_1_2_8_12_1 e_1_2_8_33_1 e_1_2_8_54_1 e_1_2_8_52_1 e_1_2_8_50_1 |
References_xml | – volume: 18 start-page: 2778 year: 2012 end-page: 2792 article-title: Tubulins as therapeutic targets in cancer: from bench to bedside publication-title: Curr Pharm Des – volume: 108 start-page: 82 year: 2013 end-page: 90 article-title: Altered TUBB3 expression contributes to the epothilone response of mitotic cells publication-title: Br J Cancer – volume: 11 start-page: 719 year: 2011 end-page: 728 article-title: Targeting βIII‐tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics publication-title: Anticancer Agents Med Chem – volume: 542 start-page: 173 year: 2014 end-page: 181 article-title: Sox9 and Hif‐2a regulate TUBB3 gene expression and affect ovarian cancer aggressiveness publication-title: Gene – volume: 51 start-page: 2183 year: 2010 end-page: 2192 article-title: Roles of hypoxia‐inducible factor‐1alpha (HIF‐1alpha) versus HIF‐2alpha in the survival of hepatocellular tumor spheroids publication-title: Hepatol Baltim Md – volume: 11 start-page: 158 year: 2009 end-page: 166 article-title: Sagopilone crosses the blood‐brain barrier in vivo to inhibit brain tumor growth and metastases publication-title: Neuro‐Oncol – volume: 15 start-page: 678 year: 2008 end-page: 685 article-title: The role of hypoxia‐inducible factors in tumorigenesis publication-title: Cell Death Differ – volume: 12 start-page: 2774 year: 2006 end-page: 2779 article-title: Class III beta‐tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients publication-title: Clin Cancer Res Off J Am Assoc Cancer Res – volume: 122 start-page: 1055 year: 2009 end-page: 1057 article-title: HIF at a glance publication-title: J Cell Sci – volume: 12 start-page: 9 year: 2012 end-page: 22 article-title: HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression publication-title: Nat Rev Cancer – volume: 66 start-page: 5641 year: 2006 end-page: 5647 article-title: Role of ETS transcription factors in the hypoxia‐inducible factor‐2 target gene selection publication-title: Cancer Res – volume: 18 start-page: 2793 year: 2012 end-page: 2803 article-title: Novel drugs targeting microtubules: the role of epothilones publication-title: Curr Pharm Des – volume: 284 start-page: 16767 year: 2009 end-page: 16775 article-title: Genome‐wide association of hypoxia‐inducible factor (HIF)‐1alpha and HIF‐2alpha DNA binding with expression profiling of hypoxia‐inducible transcripts publication-title: J Biol Chem – volume: 71 start-page: 4015 year: 2011 end-page: 4027 article-title: The hypoxia‐associated factor switches cells from HIF‐1α‐ to HIF‐2α‐dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion publication-title: Cancer Res – volume: 68 start-page: 9212 year: 2008 end-page: 9220 article-title: Hypoxia‐inducible factor‐2alpha correlates to distant recurrence and poor outcome in invasive breast cancer publication-title: Cancer Res – volume: 8 start-page: e72358 year: 2013 article-title: STAT3 or USF2 contributes to HIF target gene specificity publication-title: PLoS ONE – volume: 106 start-page: 21306 year: 2009 end-page: 21311 article-title: Human cancers converge at the HIF‐2alpha oncogenic axis publication-title: Proc Natl Acad Sci USA – volume: 20 start-page: E4 year: 2006 article-title: Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme publication-title: Neurosurg Focus – volume: 16 start-page: iv14 issue: Suppl. 4 year: 2005 end-page: iv19 article-title: Biomarkers predictive for clinical efficacy of taxol‐based chemotherapy in advanced breast cancer publication-title: Ann Oncol Off J Eur Soc Med Oncol ESMO – volume: 6 start-page: e21717 year: 2011 article-title: Specific β‐tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non‐small cell lung cancer cells publication-title: PLoS ONE – volume: 67 start-page: 9356 year: 2007 end-page: 9363 article-title: Class III beta‐tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer publication-title: Cancer Res – volume: 22 start-page: 349 year: 2010 end-page: 356 article-title: Oxygen‐sensing under the influence of nitric oxide publication-title: Cell Signal – volume: 3 start-page: 1137 year: 2004 end-page: 1146 article-title: Neuronal‐associated microtubule proteins class III beta‐tubulin and MAP2c in neuroblastoma: role in resistance to microtubule‐targeted drugs publication-title: Mol Cancer Ther – volume: 265 start-page: 73 year: 1991 end-page: 81 article-title: Changes in glial fibrillary acidic protein and karyotype during culturing of two cell lines established from human glioblastoma multiforme publication-title: Cell Tissue Res – volume: 409 start-page: 100 year: 2008 end-page: 108 article-title: Hypoxia induces class III beta‐tubulin gene expression by HIF‐1alpha binding to its 3′ flanking region publication-title: Gene – volume: 9 start-page: 412 year: 2007 end-page: 423 article-title: Antiangiogenic and anti‐invasive effects of sunitinib on experimental human glioblastoma publication-title: Neuro‐Oncol – volume: 32 start-page: 69 year: 2008 end-page: 77 article-title: Measurement of hypoxia using invasive oxygen‐sensitive electrode, pimonidazole binding and 18F‐FDG uptake in anaemic or erythropoietin‐treated mice bearing human glioma xenografts publication-title: Int J Oncol – volume: 221 start-page: 505 year: 2009 end-page: 513 article-title: Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta‐tubulin publication-title: J Cell Physiol – volume: 96 start-page: 1284 year: 2007 end-page: 1292 article-title: Target gene selectivity of hypoxia‐inducible factor‐alpha in renal cancer cells is conveyed by post‐DNA‐binding mechanisms publication-title: Br J Cancer – volume: 70 start-page: 4995 year: 2010 end-page: 5003 article-title: betaIII‐tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non‐small cell lung cancer publication-title: Cancer Res – volume: 83 start-page: 1 year: 2012 end-page: 9 article-title: Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single‐institution phase I/II trial publication-title: Oncology – volume: 25 start-page: 5675 year: 2005 end-page: 5686 article-title: Contrasting properties of hypoxia‐inducible factor 1 (HIF‐1) and HIF‐2 in von Hippel‐Lindau‐associated renal cell carcinoma publication-title: Mol Cell Biol – volume: 9 start-page: 27 year: 1999 end-page: 33 article-title: The role of paclitaxel in the treatment of primary and metastatic brain tumors publication-title: Semin Radiat Oncol – volume: 27 start-page: 17 year: 2006 end-page: 24 article-title: Use of P‐glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs publication-title: Trends Pharmacol Sci – volume: 352 start-page: 987 year: 2005 end-page: 996 article-title: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma publication-title: N Engl J Med – volume: 26 start-page: 225 year: 2007 end-page: 239 article-title: Hypoxia in cancer: significance and impact on clinical outcome publication-title: Cancer Metastasis Rev – volume: 23 start-page: 9361 year: 2003 end-page: 9374 article-title: Differential roles of hypoxia‐inducible factor 1alpha (HIF‐1alpha) and HIF‐2alpha in hypoxic gene regulation publication-title: Mol Cell Biol – volume: 12 start-page: 149 year: 1998 end-page: 162 article-title: Cellular and developmental control of O homeostasis by hypoxia‐inducible factor 1 alpha publication-title: Genes Dev – volume: 10 start-page: 413 year: 2006 end-page: 423 article-title: Recruitment of HIF‐1alpha and HIF‐2alpha to common target genes is differentially regulated in neuroblastoma: HIF‐2alpha promotes an aggressive phenotype publication-title: Cancer Cell – volume: 7 start-page: 2070 year: 2008 end-page: 2079 article-title: Proteomic characterization of cytoskeletal and mitochondrial class III beta‐tubulin publication-title: Mol Cancer Ther – volume: 51 start-page: 1882 year: 2011 end-page: 1892 article-title: Opposite effects of HIF‐1α and HIF‐2α on the regulation of IL‐8 expression in endothelial cells publication-title: Free Radic Biol Med – volume: 73 start-page: 6230 year: 2013 end-page: 6242 article-title: Tumor cells upregulate normoxic HIF‐1α in response to doxorubicin publication-title: Cancer Res – volume: 125 start-page: 613 year: 2001 end-page: 624 article-title: Aberrant localization of the neuronal class III beta‐tubulin in astrocytomas publication-title: Arch Pathol Lab Med – volume: 227 start-page: 1034 year: 2012 end-page: 1041 article-title: Class III β‐tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer publication-title: J Cell Physiol – volume: 9 start-page: 790 year: 2010 end-page: 803 article-title: Microtubule‐binding agents: a dynamic field of cancer therapeutics publication-title: Nat Rev Drug Discov – volume: 65 start-page: 2277 year: 2005 end-page: 2286 article-title: Targeted replacement of hypoxia‐inducible factor‐1alpha by a hypoxia‐inducible factor‐2alpha knock‐in allele promotes tumor growth publication-title: Cancer Res – volume: 110 start-page: 1309 year: 2002 end-page: 1318 article-title: Transport of paclitaxel (Taxol) across the blood‐brain barrier in vitro and in vivo publication-title: J Clin Invest – volume: 29 start-page: 297 year: 2003 end-page: 307 article-title: Tumour hypoxia, chemotherapeutic resistance and hypoxia‐related therapies publication-title: Cancer Treat Rev – volume: 90 start-page: 791 year: 2005 end-page: 797 article-title: Hypoxia‐inducible factor as a physiological regulator publication-title: Exp Physiol – volume: 394 start-page: 529 year: 2013 end-page: 539 article-title: Noninvasive assessment of hypoxia with 3‐[18F]‐fluoro‐1‐(2‐nitro‐1‐imidazolyl)‐2‐propanol ([18F]‐FMISO): a PET study in two experimental models of human glioma publication-title: Biol Chem – volume: 15 start-page: 2445 year: 2001 end-page: 2453 article-title: HIF‐1 is expressed in normoxic tissue and displays an organ‐specific regulation under systemic hypoxia publication-title: FASEB J Off Publ Fed Am Soc Exp Biol – volume: 10 start-page: 194 year: 2010 end-page: 204 article-title: Microtubules and resistance to tubulin‐binding agents publication-title: Nat Rev Cancer – start-page: 3431 year: 2013 article-title: betaIII‐tubulin in glioblastoma: an emerging multifactorial survival factor role in chemotherapy response and tumor formation publication-title: Proc 104th Annu Meet Am Assoc Cancer Res – volume: 4 start-page: 2001 year: 2005 end-page: 2007 article-title: Class III beta‐tubulin expression in tumor cells predicts response and outcome in patients with non‐small cell lung cancer receiving paclitaxel publication-title: Mol Cancer Ther – volume: 117 start-page: e207 year: 2011 end-page: e217 article-title: High‐resolution genome‐wide mapping of HIF‐binding sites by ChIP‐seq publication-title: Blood – volume: 37 start-page: 364 year: 2012 end-page: 372 article-title: Passing the baton: the HIF switch publication-title: Trends Biochem Sci – volume: 18 start-page: 4528 year: 2007 end-page: 4542 article-title: The N‐terminal transactivation domain confers target gene specificity of hypoxia‐inducible factors HIF‐1alpha and HIF‐2alpha publication-title: Mol Biol Cell – volume: 5 start-page: 437 year: 2004 end-page: 448 article-title: HIF1 and oxygen sensing in the brain publication-title: Nat Rev Neurosci – volume: 17 start-page: 3005 year: 1998 end-page: 3015 article-title: HIF‐1 alpha is required for solid tumor formation and embryonic vascularization publication-title: EMBO J – volume: 52 start-page: 655 year: 1993 end-page: 666 article-title: Differential localization of class III, beta‐tubulin isotype and calbindin‐D28k defines distinct neuronal types in the developing human cerebellar cortex publication-title: J Neuropathol Exp Neurol – volume: 227 start-page: 514 year: 2012 end-page: 524 article-title: Functional regulation of HIF‐1α under normoxia–is there more than post‐translational regulation? publication-title: J Cell Physiol – volume: 19 start-page: 60 year: 2009 end-page: 66 article-title: Hypoxia inducible factor‐2alpha: a critical mediator of aggressive tumor phenotypes publication-title: Curr Opin Genet Dev – volume: 15 start-page: 501 year: 2009 end-page: 513 article-title: Hypoxia‐inducible factors regulate tumorigenic capacity of glioma stem cells publication-title: Cancer Cell – ident: e_1_2_8_21_1 doi: 10.1038/nrc2803 – ident: e_1_2_8_7_1 doi: 10.1158/0008-5472.CAN-07-0509 – ident: e_1_2_8_48_1 doi: 10.1093/emboj/17.11.3005 – ident: e_1_2_8_36_1 doi: 10.1215/15228517-2007-024 – ident: e_1_2_8_25_1 doi: 10.1007/s10555-007-9055-1 – ident: e_1_2_8_15_1 doi: 10.1016/j.tips.2005.11.009 – ident: e_1_2_8_58_1 doi: 10.1158/0008-5472.CAN-08-1135 – volume: 20 start-page: E4 year: 2006 ident: e_1_2_8_3_1 article-title: Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme publication-title: Neurosurg Focus – ident: e_1_2_8_60_1 doi: 10.1158/0008-5472.CAN-10-4142 – ident: e_1_2_8_2_1 doi: 10.1056/NEJMoa043330 – ident: e_1_2_8_11_1 doi: 10.1002/jcp.22813 – ident: e_1_2_8_12_1 doi: 10.1371/journal.pone.0021717 – ident: e_1_2_8_23_1 doi: 10.2174/187152011797378760 – ident: e_1_2_8_10_1 doi: 10.1158/1535-7163.MCT-07-2370 – ident: e_1_2_8_54_1 doi: 10.1182/blood-2010-10-314427 – ident: e_1_2_8_45_1 doi: 10.1016/j.freeradbiomed.2011.08.023 – ident: e_1_2_8_49_1 doi: 10.1016/j.cellsig.2009.10.004 – ident: e_1_2_8_5_1 doi: 10.1097/00005072-199311000-00013 – ident: e_1_2_8_40_1 doi: 10.1158/1078-0432.CCR-05-2715 – ident: e_1_2_8_18_1 doi: 10.1159/000339152 – ident: e_1_2_8_32_1 doi: 10.1158/0008-5472.CAN-04-3246 – ident: e_1_2_8_51_1 doi: 10.1158/0008-5472.CAN-12-1345 – ident: e_1_2_8_17_1 doi: 10.1215/15228517-2008-072 – ident: e_1_2_8_55_1 doi: 10.1038/sj.bjc.6603675 – ident: e_1_2_8_8_1 doi: 10.4161/cbt.3.11.1216 – ident: e_1_2_8_29_1 doi: 10.1128/MCB.23.24.9361-9374.2003 – ident: e_1_2_8_31_1 doi: 10.1128/MCB.25.13.5675-5686.2005 – ident: e_1_2_8_50_1 doi: 10.1002/jcp.22798 – ident: e_1_2_8_33_1 doi: 10.1038/nrc3183 – ident: e_1_2_8_14_1 doi: 10.1172/JCI0215451 – ident: e_1_2_8_24_1 doi: 10.1016/S0305-7372(03)00003-3 – ident: e_1_2_8_52_1 doi: 10.1002/hep.23597 – volume: 32 start-page: 69 year: 2008 ident: e_1_2_8_38_1 article-title: Measurement of hypoxia using invasive oxygen‐sensitive electrode, pimonidazole binding and 18F‐FDG uptake in anaemic or erythropoietin‐treated mice bearing human glioma xenografts publication-title: Int J Oncol – ident: e_1_2_8_47_1 doi: 10.1101/gad.12.2.149 – ident: e_1_2_8_56_1 doi: 10.1158/0008-5472.CAN-05-3345 – ident: e_1_2_8_26_1 doi: 10.1038/cdd.2008.21 – ident: e_1_2_8_37_1 doi: 10.1515/hsz-2012-0318 – ident: e_1_2_8_57_1 doi: 10.1371/journal.pone.0072358 – volume: 9 start-page: 27 year: 1999 ident: e_1_2_8_16_1 article-title: The role of paclitaxel in the treatment of primary and metastatic brain tumors publication-title: Semin Radiat Oncol – ident: e_1_2_8_61_1 doi: 10.1016/j.ccr.2006.08.026 – ident: e_1_2_8_59_1 doi: 10.1016/j.gde.2008.12.001 – ident: e_1_2_8_19_1 doi: 10.2174/138161212800626238 – ident: e_1_2_8_62_1 doi: 10.1073/pnas.0906432106 – ident: e_1_2_8_6_1 doi: 10.5858/2001-125-0613-ALOTNC – ident: e_1_2_8_20_1 doi: 10.1038/bjc.2012.553 – ident: e_1_2_8_22_1 doi: 10.2174/138161212800626193 – ident: e_1_2_8_41_1 doi: 10.1093/annonc/mdi902 – ident: e_1_2_8_4_1 doi: 10.1002/jcp.21870 – ident: e_1_2_8_42_1 doi: 10.1158/1535-7163.MCT-05-0244 – ident: e_1_2_8_63_1 doi: 10.1016/j.ccr.2009.03.018 – ident: e_1_2_8_35_1 doi: 10.1016/j.gene.2014.03.037 – ident: e_1_2_8_34_1 doi: 10.1016/j.gene.2007.11.015 – ident: e_1_2_8_46_1 doi: 10.1096/fj.01-0125com – ident: e_1_2_8_64_1 doi: 10.1007/BF00318141 – ident: e_1_2_8_9_1 doi: 10.1038/nrd3253 – ident: e_1_2_8_39_1 doi: 10.1016/j.tibs.2012.06.004 – ident: e_1_2_8_27_1 doi: 10.1242/jcs.035022 – ident: e_1_2_8_53_1 doi: 10.1074/jbc.M901790200 – start-page: 3431 year: 2013 ident: e_1_2_8_43_1 article-title: betaIII‐tubulin in glioblastoma: an emerging multifactorial survival factor role in chemotherapy response and tumor formation publication-title: Proc 104th Annu Meet Am Assoc Cancer Res – ident: e_1_2_8_13_1 doi: 10.1158/0008-5472.CAN-09-4487 – ident: e_1_2_8_44_1 doi: 10.1091/mbc.e06-05-0419 – ident: e_1_2_8_28_1 doi: 10.1113/expphysiol.2005.030924 – ident: e_1_2_8_30_1 doi: 10.1038/nrn1408 |
SSID | ssj0035499 |
Score | 2.2930326 |
Snippet | Glioblastoma multiforme (GBM) is the deadliest form of primary brain cancer. Several reports have indicated aberrant levels of βIII‐tubulin (βIII‐t) in human... Glioblastoma multiforme (GBM) is the deadliest form of primary brain cancer. Several reports have indicated aberrant levels of βIII-tubulin (βIII-t) in human... Glioblastoma multiforme (GBM) is the deadliest form of primary brain cancer. Several reports have indicated aberrant levels of beta III-tubulin ( beta III-t)... |
SourceID | hal proquest pubmed crossref wiley fao |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 5220 |
SubjectTerms | Base Sequence Basic Helix-Loop-Helix Transcription Factors - genetics Basic Helix-Loop-Helix Transcription Factors - physiology Binding Sites brain Brain Neoplasms - metabolism Brain Neoplasms - pathology Cell Hypoxia Cell Line, Tumor cultured cells drug therapy gel electrophoresis genes Glioblastoma - metabolism Glioblastoma - pathology glioblastoma cells HIF‐1α HIF‐2α Humans hypoxia hypoxia-inducible factor 1 Hypoxia-Inducible Factor 1, alpha Subunit - genetics Hypoxia-Inducible Factor 1, alpha Subunit - physiology Life Sciences Molecular Sequence Data neoplasms normoxia promoter regions Promoter Regions, Genetic response elements RNA, Small Interfering - genetics site-directed mutagenesis tubulin Tubulin - genetics βIII‐tubulin |
Title | Hypoxia‐inducible factor‐2α (HIF‐2α), but not HIF‐1α, is essential for hypoxic induction of class III β‐tubulin expression in human glioblastoma cells |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Ffebs.13062 https://www.ncbi.nlm.nih.gov/pubmed/25244496 https://www.proquest.com/docview/1628238695 https://www.proquest.com/docview/1694978394 https://www.proquest.com/docview/2000013213 https://hal.science/hal-01626225 |
Volume | 281 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwELVKX-CFSws0XKrhIkRRU21ix0kkXpbS1S63B8pK-1JFtmO3K5akYhPU8sQn8BH8QPmQ_Qi-hLGzWSiXSvASRdbYsuMz9owzPkPI_UBrjvtK6keRUD5TJvaFYdqn3OQxi-JQuktiL1_x_pA9G0WjJfK4vQvT8EMsDtysZrj12iq4kNOflNxoObW5jN0CHFBuifOfvl5wR1Hr-DS3IUOfcTaac5PaMJ4fVU_tRueMKPF5YCMifzc3T1uvbvvpXSJ7bcebqJO3W3Ult9THXzgd_3dkl8nFuV0K3QZIV8iSLlbIardAn_zdMTwAFynqjuBXyPntNkvcKvnSPz4sj8bi26fP6N3XaiwnGpokPlgUzk7gYX_Qa143NkHWFRRlBU1ZMDvZhPEULH95gUvNBNCEhgPXogLXnsUNlAaUtfJhMBjA7CvWrGppQ-hBH80DeQsUB5dwEPYn41KiOPZcgP0xMb1Khr2dN9t9f575wVcsSUM_EJ2OjmRCqdRpkuc0VkrRpGNTLYmOsbmOQp6bSPEgTwwWJwgwEciUWUG0yK6R5aIs9BoBSoWOU0EjrhF7OpSKmkSiEWgCluuYemSjRUCm5rToNjvHJGvdIzsdmZsOj9xbyB42ZCB_lFpDIGViH1fpbLgbWg4_x4OTxB65i-ha1LXU3v3ui8yWoVTIcXH9EHjkTgu-DCfTfidR6LLG5jk6yDThaXSWTGqTBtKU_V0mdP90aBjg6K836F70KYzQ4GMp98gjh9EzBpr1dp7surcb_yJ8k1zAb8KamKBbZLl6X-vbaNlVch01ePB83enxdzzwT50 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwELWgPJQXLi3Q5WouQhQ11SZ2bo9L6SoL2z7QrrRvke3Y7YolqdgEtTzxCXwEP1A-ZD-CL2HGyQbKpRK8RJE1tuJ4PD5jj88Q8sTVOoB1JXZ8XyiHKxM6wnDtsMBkIfdDT9pLYju7QTLir8b-uInNwbswNT9Eu-GGM8Paa5zguCH90yw3Ws4wmTFa4EsckAb6Xi_ftOxRDF2f-j6k5_CAjxt2Ugzk-VH3zHp00YgCnocYE_k74DyLX-0C1L9aZ1mdWd5CjDt5u1mVclN9_IXV8b_7do1caaAp7dW6dJ1c0PkKWe3l4Ja_O6FPqQ0WtbvwK2R5a5EobpV8SU6OiuOJ-PbpMzj4lZrIqaZ1Hh8o8uan9Fky6Nev6xtUViXNi5LWZe78dINOZhQpzHOwNlMKKJoe2hYVte2h6tDCUIVAnw4GAzr_CjXLSmIUPdXHTSxvDuLU5hykB9NJIUEcvlxQPJuY3SCj_vb-VuI0yR8cxaPYc1zR7WpfRoxJHUdZxkKlFIu6mG1JdA2mO_KCzPgqcLPIQHEEOiZcGXMUBFB2kyzlRa7XCGVM6DAWzA80qJ_2pGImkoADjcszHbIOWV-oQKoaZnRM0DFNFx4SDkdqh6NDHreyRzUfyB-l1kCTUnEAhjod7XlI42epcKKwQx6BerV1kd076Q1TLAMpLwD7-sHtkIcL7UthMPE_iVwXFTQfgI_MoiD2z5OJMW8gi_nfZTx7rMM8F3p_q1bv9ps8HzAfj4MOeW6V9JyOpv3tF3v27fa_CD8gy8n-zjAdDnZf3yGX4f_wOkToLlkq31f6HgC9Ut630_k7GcpSww |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwELVKkYAXLi3Q5WouQhQ11SZ2nETipZSudqFUiLLSvqDIdux2xZKs2AS1PPEJfAQ_UD5kP4IvYcbZLJRLJXiJImts2fF4fMYZnyHkvm-MgH0l8cJQao9rG3nScuMxYbOIh1Gg3CWxFzui2-fPBuFggTxu7sLU_BDzAzdcGc5e4wIfZ_anRW6NmmAuYzTAp7kAKIGQ6NWcPIqh51Nfhww8LvhgRk6KcTw_6h7bjk5ZWcBzH0Mif8ebx-Gr2386F8ibpud12Mnb9apU6_rjL6SO_zu0i-T8DJjSjVqTLpEFky-R5Y0cnPJ3h_QBdaGi7gx-iZzdbNLELZMv3cNxcTCU3z59Bve-0kM1MrTO4gNFwfSIPuz2OvXr6hpVVUnzoqR1mT89WqPDCUUC8xxszYgChqb7rkVNXXuoOLSwVCPMp71ej06_Qs2yUhhDT83BLJI3B3HqMg7SvdGwUCAOPZcU_0xMLpN-Z-v1ZtebpX7wNI-TwPNlu21CFTOmTBJnGYu01ixuY64l2baY7CgQmQ218LPYQnEMGiZ9lXAUBEh2hSzmRW5WCGVMmiiRLBQGlM8ESjMbK0CB1ueZiViLrDYakOoZLzqm5xiljX-E05G66WiRe3PZcc0G8kepFVCkVO6BmU77uwGS-DkinDhqkbugXfO6yO3d3dhOsQykAgHW9YPfInca5UthMvE7ydwUFTQvwENmsUjCk2QSzBrIEv53mcD91GGBD6O_Wmv3vE9BCIiPJ6JFHjkdPWGgaWfrya57u_YvwrfJmZdPO-l2b-f5dXIOPg-v44NukMXyfWVuAsor1S23mL8D8RhRcg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hypoxia%E2%80%90inducible+factor%E2%80%902%CE%B1+%28HIF%E2%80%902%CE%B1%29%2C+but+not+HIF%E2%80%901%CE%B1%2C+is+essential+for+hypoxic+induction+of+class+III+%CE%B2%E2%80%90tubulin+expression+in+human+glioblastoma+cells&rft.jtitle=The+FEBS+journal&rft.au=Bordji%2C+Karim&rft.au=Grandval%2C+Alexandra&rft.au=Cuhna%E2%80%90Alves%2C+Leilane&rft.au=Lechapt%E2%80%90Zalcman%2C+Emmanu%C3%A8le&rft.date=2014-12-01&rft.issn=1742-464X&rft.eissn=1742-4658&rft.volume=281&rft.issue=23&rft.spage=5220&rft.epage=5236&rft_id=info:doi/10.1111%2Ffebs.13062&rft.externalDBID=10.1111%252Ffebs.13062&rft.externalDocID=FEBS13062 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1742-464X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1742-464X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1742-464X&client=summon |